Roivant Sciences Ltd.
ROIV · Nasdaq · United States · Health Care · Pharma / Biotech / Life Sci
- Coverage
- FY2020–FY2026
- History
- 7 years
- Latest filing
- 10-K · SEC EDGAR
- Reporting
- USD
- Fiscal year end
- March
- Last updated
- May 2026
Headline figures
Roivant Sciences Ltd. at a glance
In FY2026, Roivant Sciences Ltd. reported revenue of USD 8,260 thousands, EBITDA of USD -1,280,670 thousands, free cash flow of USD -758,558 thousands.
| USD thousands | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Revenue | 29,053 | 8,260 | |||
| EBITDA | -1,098,699 | -1,280,670 | |||
| Free cash flow | -844,050 | -758,558 |
The full 7-year history, every line item and each formula are in the platform.
In the platform
- Stat Book — normalized and as-reported IS, BS and CF
- Up to 10 years of annual and quarterly history
- Peer benchmarking and the stock screener
- Corporate risk scorecard
- DCF model from the filed inputs
- Tearsheet and live Excel formulas